LC
SMMT icon

Lindbrook Capital’s Summit Therapeutics SMMT Stock Holding History

Lindbrook Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$16.3K Buy
843
+88
+12% +$1.76K ﹤0.01% 1446
2024
Q4 		$13.5K Hold
755
– – ﹤0.01% 1491
2024
Q3 		$16.5K Sell
755
-56
-7% -$783 ﹤0.01% 1396
2024
Q2 		$6.33K Buy
811
+284
+54% +$1.53K ﹤0.01% 1881
2024
Q1 		$2.18K Hold
527
– – ﹤0.01% 2214
2023
Q4 		$1.38K Sell
527
-255
-33% -$525 ﹤0.01% 2389
2023
Q3 		$1.46K Buy
782
+42
+6% +$80 ﹤0.01% 2231
2023
Q2 		$1.86K Sell
740
-3,426
-82% -$6.25K ﹤0.01% 2175
2023
Q1 		$7.29K Buy
4,166
+3,870
+1,307% +$10.6K ﹤0.01% 1658
2022
Q4 		$1.26K Buy
+296
New +$538 ﹤0.01% 2410
2022
Q1 		– Sell
-148
Closed – – 2605
2021
Q4 		$0 Sell
148
-115
-44% -$553 ﹤0.01% 2194
2021
Q3 		$1K Sell
263
-417
-61% -$2.99K ﹤0.01% 1779
2021
Q2 		$5K Sell
680
-197
-22% -$1.29K ﹤0.01% 1307
2021
Q1 		$5K Buy
877
+34
+4% +$219 ﹤0.01% 1273
2020
Q4 		$4K Buy
+843
New +$3.57K ﹤0.01% 1280

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Lindbrook Capital's SMMT Position: Q1 2025 in Review

Lindbrook Capital increased its Summit Therapeutics (SMMT) stake by 12% in Q1 2025, buying an estimated $1.76K and bringing the position to 843 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1446.

Lindbrook Capital first reported a position in SMMT in Q4 2020 and has held it in 15 quarters since. The position peaked at $16.5K in Q3 2024. 212 funds tracked by Wall St. Rank hold SMMT as of Q1 2025.

  • Lindbrook Capital held 843 shares of Summit Therapeutics worth $16.3K as of Q1 2025.
  • Lindbrook Capital bought 88 Summit Therapeutics shares in Q1 2025, an estimated $1.76K.
  • Summit Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1446 holding.
  • Lindbrook Capital first reported a position in Summit Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Lindbrook Capital's Summit Therapeutics position peaked at $16.5K in Q3 2024.
  • 212 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.